PolarityTE, Inc. (PTE)
Stock Price:
$1.45 USD
0.00 (0.00%)
Updated Aug 12, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
56.17M |
| Revenue (ttm) |
6.06M |
| Net Income (ttm) |
-69.85M |
| Shares Out |
38.74M |
| EPS (ttm) |
-2.24 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 12, 2020 |
| Last Price |
$1.45 |
| Previous Close |
$1.45 |
| Change ($) |
0.00 |
| Change (%) |
0.00% |
| Day's Open |
1.45 |
| Day's Range |
1.40 - 1.52 |
| Day's Volume |
294,746 |
| 52-Week Range |
0.78 - 5.62 |
More Stats
| Market Cap |
56.17M |
| Enterprise Value |
31.71M |
| Earnings Date (est) |
Nov 17, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
38.74M |
| Float |
25.88M |
| EPS (basic) |
-2.35 |
| EPS (diluted) |
-2.24 |
| FCF / Share |
-1.43 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
2.86M |
| Short Ratio |
3.14 |
| Short % of Float |
9.79% |
| Beta |
1.83 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
9.27 |
| PB Ratio |
1.40 |
| Revenue |
6.06M |
| Operating Income |
-73.31M |
| Net Income |
-69.85M |
| Free Cash Flow |
-55.11M |
| Net Cash |
24.47M |
| Net Cash / Share |
0.63 |
| Gross Margin |
52.36% |
| Operating Margin |
-1,209.79% |
| Profit Margin |
-1,152.60% |
| FCF Margin |
-909.32% |
| ROA |
-60.69% |
| ROE |
-139.78% |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (5)
| Buy |
3 |
| Overweight |
0 |
| Hold |
2 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$3.33*
(129.66% upside)
Low
3.00
Current: $1.45
High
4.00
Target: 3.33
*Average 12-month price target from 3 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 5.65 | 1.56 | - | - | 6.69 | 34.37 | 47.27 | 132 | 125 | 75.65 |
| Revenue Growth | 261.61% | - | - | - | -80.53% | -27.29% | -64.27% | 5.58% | 65.62% | - |
| Gross Profit | 3.17 | 0.56 | - | - | 3.27 | 5.71 | 12.17 | 43.52 | 45.48 | 18.39 |
| Operating Income | -93.39 | -69.43 | -131 | -4.10 | -3.93 | -13.33 | -12.24 | 3.71 | 11.36 | -2.11 |
| Net Income | -92.49 | -65.44 | -131 | -4.64 | -3.81 | -16.20 | -12.64 | 4.61 | 6.83 | -0.97 |
| Shares Outstanding | 24.97 | 15.26 | 4.92 | 2.10 | 1.23 | 1.07 | 0.99 | 0.95 | 0.92 | 0.88 |
| Earnings Per Share | -3.70 | -4.29 | -26.57 | -2.21 | -4.93 | -15.12 | -12.78 | 4.62 | 7.14 | -1.26 |
| EPS Growth | - | - | - | - | - | - | - | -35.29% | - | - |
| Operating Cash Flow | -56.65 | -28.55 | -7.58 | -1.77 | -1.61 | -3.51 | -4.59 | 6.09 | 9.42 | -3.04 |
| Capital Expenditures | -2.77 | -9.22 | -2.54 | - | 0.29 | -0.35 | -0.27 | -0.34 | -0.47 | -0.28 |
| Free Cash Flow | -59.42 | -37.77 | -10.13 | -1.77 | -1.32 | -3.86 | -4.86 | 5.75 | 8.95 | -3.32 |
| Cash & Equivalents | 29.24 | 70.96 | 17.67 | 6.52 | 17.05 | 7.45 | 13.39 | 18.04 | 13.69 | 8.00 |
| Total Debt | 3.52 | 1.26 | - | - | - | - | 1.76 | - | 1.24 | 5.56 |
| Net Cash / Debt | 25.72 | 69.71 | 17.67 | 6.52 | 17.05 | 7.45 | 11.62 | 18.04 | 12.45 | 2.45 |
| Assets | 53.60 | 87.84 | 20.15 | 6.75 | 17.66 | 11.46 | 37.65 | 49.30 | 52.38 | 30.03 |
| Liabilities | 14.68 | 6.18 | 15.44 | 1.35 | 2.00 | 5.91 | 17.60 | 19.96 | 29.14 | 18.02 |
| Book Value | 38.92 | 81.66 | 0.17 | 5.40 | 15.66 | 5.55 | 20.05 | 29.34 | 23.24 | 12.01 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
PolarityTE, Inc. |
| Country |
United States |
| Employees |
153 |
| CEO |
David Seaburg |
Stock Information
| Ticker Symbol |
PTE |
| Stock Exchange |
NASDAQ |
| Sector |
Financial |
| Industry |
Closed-End Fund - Equity |
| Unique Identifier |
NASDAQ: PTE |
| IPO Date |
August 13, 1999 |
Description
PolarityTE, Inc., a biotechnology and regenerative biomaterials company, develops and commercializes a range of regenerative tissue products and biomaterials for the fields of medicine, biomedical engineering, and material sciences in the United States. The company operates in two segments, Regenerative Medicine and Contract Services. It offers SkinTE, a tissue product for treatment of defects of the skin, as well as contract research services; SkinTE point-of-care device to permit the processing and deployment of SkinTE immediately following the initial harvest at the point-of-car; and PTE 11000, an allogenic, biologically active dressing for use in wound care and aesthetics to accelerate healing of skin. The company also develops OsteoTE, an autologous homologous bone regeneration product; and CartTE, an autologous cartilage regeneration product. In addition, it develops AdipoTE to optimize the delivery of autologous fat; AngioTE for vascular regeneration; NeuralTE for peripheral nerve injuries of the extremities, as well as for patients with neuromas or chronic compression due to joint replacements, migraines, craniofacial injuries, carpal tunnel syndrome, and those who have undergone hernia or abdominal-based procedures; UroTE for the delivery of autologous urogenital epithelium and submucosa; LiverTE to address various causes of liver failure; and BowelTE to deliver an optimized autologous construct to aid in the regeneration of bowel tissue. PolarityTE, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah.